Maapliv
What Maapliv is used for
Maapliv is indicated for the treatment of maple syrup urine disease (MSUD) presenting with an acute decompensation episode in patients from birth who are not eligible for an oral and enteral branched-chain amino acids free (BCAA- free) formulation.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Maapliv
- Active substance
- amino acids
- Disease area
- Maple Syrup Urine Disease
- Medicine group
- Blood substitutes and perfusion solutions
- ATC code
- B05BA01
- Marketing authorisation holder
- Recordati Rare Diseases
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Maapliv used for?
Maapliv is indicated for the treatment of maple syrup urine disease (MSUD) presenting with an acute decompensation episode in patients from birth who are not eligible for an oral and enteral branched-chain amino acids free (BCAA- free) formulation.
What is the active substance in Maapliv?
Maapliv contains amino acids.
Who makes Maapliv?
The EU marketing authorisation holder is Recordati Rare Diseases.
Is Maapliv an orphan medicine?
Yes. Maapliv is designated an orphan medicine in the EU, for a rare disease (Maple Syrup Urine Disease).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU